Business
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demon...
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n - Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the\n \n\n clinical benefits of CASGEVY\n \n ®\n \n -\n \n\n\n\n - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -\n \n\n\n\n\n TORONTO\n \n\n ,\n \n\n July 3, 2025\n \n\n /CNW/ -\n \n Vertex Pharmaceuticals\n \n (Nasdaq: VRTX) recently announced positive longer-term data for\n \n Pr\n \n CASGEVY\n \n ®\n \n (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy.\n \n\n\n\n\n\n\n\n\n \"This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia,\" said\n \n Kevin Kuo\n \n , M.D., Hematologist and Associate Professor in the Division of Hematology,\n \n University of Toronto\n \n , Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. \"These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need.\"\n \n\n\n New longer-term follow-up data presented from the CASGEVY trials\n \n\n\n\n In SCD, 43/45 (95.6%) evaluable patients (those with at...